首頁 › 多發性骨髓瘤 › 北卡羅來納州 › Charlotte
Charlotte, NC 的 多發性骨髓瘤 臨床試驗
21 項針對 多發性骨髓瘤 的研究正在 Charlotte（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
招募中3 期
- Research Site, Charlotte
- Research Site, Charlotte
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
招募中1 期
- Levine Cancer Institute, Charlotte
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
招募中4 期
- Levine Cancer Institute, Charlotte
A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel
招募中2 期
- Atrium Health, Charlotte
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
招募中3 期
- Levine Cancer Institute, Charlotte
- Novant Health, Charlotte
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
招募中1/2 期
- Atrium Health Levine Cancer Institute, Charlotte
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
招募中2 期
- Atrium Health's Levine Cancer Institute, Charlotte
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
招募中3 期
- Levine Cancer Institute, Charlotte
- Levine Cancer Institute, Charlotte
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
招募中1/2 期
- Atrium Health Levine Cancer Institute /ID# 271510, Charlotte
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
招募中3 期
- Novant Health Cancer Institute, Charlotte
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
招募中1 期
- Atrium Health, Levine Cancer Institute, Charlotte
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
招募中1/2 期
- Research Site, Charlotte
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
招募中3 期
- Research Site, Charlotte
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
招募中1/2 期
- Atrium Health Levine Cancer Institute /ID# 276193, Charlotte
CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study
招募中觀察性研究歡迎健康志工
- Atrium Health Levine Cancer, Charlotte
Pre-malignant States to Hematologic Malignancies in Firefighters
招募中觀察性研究歡迎健康志工
- Levine Cancer Institute, Charlotte
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
招募中3 期
- Levine Cancer Institute, Charlotte
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
招募中2 期
- Levine Cancer Institute, Charlotte
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
招募中1/2 期
- Levine Cancer Institute, Charlotte
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
招募中3 期
- GSK Investigational Site, Charlotte
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
招募中1 期
- Levine Cancer Institute, Charlotte
其他城市的 多發性骨髓瘤 試驗
- New York City, NY60 項研究
- Boston, MA42 項研究
- Atlanta, GA42 項研究
- Houston, TX38 項研究
- Durham, NC37 項研究
- Nashville, TN32 項研究
- Denver, CO27 項研究
- St. Louis, MO24 項研究
- Rochester, MN24 項研究
- Columbus, OH24 項研究
- Baldwin Park, CA23 項研究
- Edison, NJ22 項研究
Charlotte 的其他研究
- 癌症（所有類型）27 項研究
- 乳癌22 項研究
- 非小細胞肺癌19 項研究
- 急性髓系白血病16 項研究
- 肥胖症16 項研究
- 過重15 項研究
- 大腸直腸癌13 項研究
- 卵巢癌12 項研究
- 心臟衰竭11 項研究
- 轉移性癌症11 項研究
- 頭頸部鱗狀細胞癌10 項研究
- 慢性阻塞性肺病9 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。